78 episódios

The Onco'Zine Brief is an interview and discussion program presented by Peter Hofland, Ph.D., covering a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world.

The Onco'Zine Brief is a sponsor-supported, program for healthcare professionals involved in the management and care of cancer patients as well as cancer patients and their family and friends.

The Onco'Zine Brief Peter Hofland, Ph.D

    • Ciência

The Onco'Zine Brief is an interview and discussion program presented by Peter Hofland, Ph.D., covering a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world.

The Onco'Zine Brief is a sponsor-supported, program for healthcare professionals involved in the management and care of cancer patients as well as cancer patients and their family and friends.

    Richard Schilsky, M.D. - A Deep Passion for Cancer Medicine

    Richard Schilsky, M.D. - A Deep Passion for Cancer Medicine

    In this episode of The Onco’Zine Brief Peter Hofland talks with Richard Schilsky, M.D.

    Dr. Schilsky, the Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO), is an oncologist who specializes in new drug development and treatment of gastrointestinal cancers. His impressive experience and many accomplishments in both clinical medicine and clinical research, reflect his deep passion for cancer medicine.

    As a highly respected leader in the field of clinical oncology, Dr. Schilsky has spent the majority of his career at the University of Chicago, where he joined the faculty in 1984.
    In 2013 he joined ASCO where he launched ASCO’s first-ever prospective clinical trial, the Targeted Agent and Profiling Utilization Registry or TAPUR Study.

    Dr. Schilsky also established the Center for Research & Analytics, developed a Board-approved Policy on Research Scope, set up a process to review and fulfill requests for ASCO data, built a Division of Biostatistics and Research Data Governance, and initiated ASCO’s Research Survey Pool to support surveys of ASCO members for research purposes.

    Being at the forefront of cancer medicine, Dr. Schilsky also worked on developing ASCO’s CancerLinQ which helped define a real-world evidence research strategy in cancer care, recognizing early on that big data can help us to learn from every patient’s cancer experience—not just from the 3% of patients who are able to participate in clinical trials.

    In February 2021 Dr. Schilsky will be retiring from his role of chief medical officer at the American Society of Clinical Oncology. In the interview today Hofland and Schilsky talk about progress made in the treatment of cancer.

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief

    For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

    To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

    • 49 min
    Pascal Touchon: A Mission to Transform the Lives of Patients with Serious Medical Conditions

    Pascal Touchon: A Mission to Transform the Lives of Patients with Serious Medical Conditions

    In this episode of The Onco’Zine Brief Peter Hofland talks with Pascal Touchon, President, Chief Executive Officer, and member of the Board of Directors Atara Biotherapeutics.

    With more than 30 years of global biopharmaceutical leadership experience, Pascal Touchon has committed his career to transform the lives of patients with serious medical conditions.

    Before joining Atara Biotherapeutics Dr. Touchon was Global Head, Cell & Gene and member of the Oncology Executive Committee at Novartis Oncology, where he was responsible for the global launch of Novartis’ CAR T-cell drug and expanded global CAR T-cell manufacturing and technical operations.

    Now, at Atara Biotherapeutics, Dr. Touchon guides the company in developing the next-generation of off-the-shelf CAR T-cell immunotherapies, using a technology platform that makes it possible to manufacture a T-cell library in advance of a patient’s specific medical needs.

    The company is developing a host of potentially transformative T-cell immunotherapies for cancer, autoimmune, and viral diseases, using Epstein-Barr Virus T-Cells from donors with a healthy immune function.

    Epstein-Barr Virus is associated with a wide range of hematological malignancies and solid tumors, as well as certain autoimmune conditions such as multiple sclerosis.

    Among the novel therapies the company is developing, is ATA3271, a next-generation, off-the-shelf, allogeneic Epstein-Barr Virus CAR T-cell therapy targeting mesothelin, a cell surface antigen that is strongly expressed in mesothelial cells and is highly expressed in pancreatic cancers, ovarian cancers, mesotheliomas, and some other cancers.

    The investigational drug is designed for the treatment of solid tumors.

    Earlier this year, during the 35th annual meeting of the Society for Immunotherapy of Cancer (SITC) the company presented favorable findings from in vitro and in vivo evaluation of ATA3271

    During the upcoming 62nd Annual Meeting of the American Society of Hematology (ASH), being held virtually from December 5th through 8th this year, pre-clinical data of another investigational agent, ATA3219, will be presented.

    The available data shows that ATA3219 demonstrates efficient targeting of CD19-expressing tumor cells, both in vitro and in vivo

    In the interview today, originally recorded in June 2020, Hofland and Touchon talk about the company and the transformative therapies being developed for patients diagnosed with solid tumors, hematologic cancers, and autoimmune disease.

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief

    For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

    To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

    • 49 min
    Accelerate the Development of Precision Medicine Diagnostics

    Accelerate the Development of Precision Medicine Diagnostics

    In this edition of The Onco’Zine Brief Peter Hofland talks with Peter Keeling about Personalized Medicine, diagnostic testing, and the effect of Covid-19 on cancer and cancer diagnostics. Hofland and Keeling also talk about the world’s first Diagnostic Network for Precision Medicine.

    Peter Keeling is the chief executive officer and Founder of Diaceutics. Since its founding, the company has built the world’s largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries.

    The company recently launched the world’s first digital diagnostics platform solution. Diaceutics has launched this new platform – called --The Diagnostic Network® ---to help solve the many problems that exist today within the patient diagnosis process.

    A proper diagnostic test is an essential step to ensure that a patient receives the most effective treatment.

    Correctly diagnosing also leads to efficiently managing a patient’s disease, which, in turn, results in improved healthcare outcomes.

    In contrast, the failure to diagnose a condition correctly can reduce the possibility of a good healthcare outcome and limit a patient's ability to fully recover.

    Diaceutics’ network has been designed to accelerate the end-to-end development and commercialization of precision medicine diagnostics. But more importantly, the platform is designed to get every patient the treatment he or she deserves.

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief

    For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

    To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

    • 48 min
    The Burden of Chemotherapy-induced Myelosuppression

    The Burden of Chemotherapy-induced Myelosuppression

    In this episode of The Onco’Zine Brief Peter Hofland Ph.D., talks with Raj Malik M.D. and Robert Epstein M.D.

    Malik is Chief Medical Officer and Senior Vice President, R&D, at G1 Therapeutics. He leads the company’s clinical development, medical affairs, regulatory affairs, biometrics, translational medicine and preclinical teams. Epstein is an epidemiologist with extensive expertise in pharmaco-economics and health outcomes research. He served in academia and public health prior to joining the private sector and is currently the Chief Executive Officer and co-Founder of Epstein Health, providing strategic consultancy services to life sciences companies

    Hofland and his guests talk about the burden of Chemotherapy-induced Myelosuppression (CIM), which is also referred to as Bone Marrow Depression. [1]

    Chemotherapy-induced myelosuppression is a common side effect of chemotherapy. It generally ranges from mild to severe. Severe cases of myelosuppression, referred to as myeloablation, can be fatal.

    As a result, the side effects of chemotherapy-induced myelosuppression remain a major source of concern for both patients and health care providers. And the consequences include anemia, thrombocytopenia, and neutropenia, all of which can cause severe complications, and limit the ability of patients to receive chemotherapy on time and at standard-of-care doses. [1]

    Chemotherapy-induced myelosuppression is one of the most common dose-limiting complications of cancer treatment and is associated with a range of symptoms that can significantly impact patients’ health related quality of life.

    Despite the current availability and use of various supportive care interventions, chemotherapy-induced myelosuppression places a substantial burden on patients with advanced solid tumors, impacting many aspects of their daily lives

    Breakthrough Therapy
    In the program today Hofland and his guests also talk about G1 Therapeutics first-in-class FDA-designated "Breakthrough Therapy" designed to improve outcomes for people with cancer who are treated with chemotherapy and we talk about myelopreservation which may reduce chemotherapy-related toxicity, making chemotherapy safer and more tolerable, and also reduce the need for rescue interventions that address the effects of myelosuppression, such as growth factors or blood and platelet transfusions.

    Data from a study published earlier this year in advances in therapy highlights that despite the various methods used to address chemotherapy-induced myelosuppression, and the patient-focused approach of oncologists, the real-world impact of chemotherapy-induced myelosuppression on patients is substantial.

    Based on the results of the study, the authors conclude that improving communication between patients and health care providers may help improve patients’ understanding of chemotherapy-induced myelosuppression and foster shared decision-making in terms of treatment.

    For more information about chemotherapy-induced myelosuppression and GI Therapeutics visit the company’s web site at https://www.g1therapeutics.com/

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief

    For more information about cancer and cancer treatments, visit our online journal Onco'Zine at a...

    • 46 min
    Antibody-dye Conjugates – A Targeted Light Activated Anti-Cancer Treatment

    Antibody-dye Conjugates – A Targeted Light Activated Anti-Cancer Treatment

    In this episode of The Onco’Zine Brief Peter Hofland talks with Peggy Berry, Vice president of Global Regulatory Affairs at Rakuten Medical.*

    Rakuten Medical is developing a technology platform called Illuminox™ which is based on a cancer therapy called Near Infrared Photoimmunotherapy. This technology was originally developed by Hisataka Kobayashi, M.D., Ph.D. and his team at the National Cancer Institute (NCI) in the United States. [1]

    Rakuten Medical’s first investigational drug, based on it’s Illuminox™ platform technology, is called cetuximab saratolacan (previously known as ASP-1929 and RM-1929).

    Cetuximab saratolacan is an antibody-dye conjugate which includes the antibody, cetuximab (Erbitux®; Eli Lilly and Merck Serono) and a near-infrared, water-soluble, silicon-phthalocyanine derivative, photosensitizer or light activatable dye called IRdye700DX (IR700).

    The antibody-dye conjugate specifically targets the epidermal growth factor receptor or EGFR, which is broadly expressed in tumors such as head and neck cancer, gastric cancer, prostate cancer, lung and pancreatic cancers as well as glioblastoma.[2]

    The investigational agent has a unique mechanism of action. After cetuximab saratolacan is administered and binds to EGFRs on tumor cells, the drug is locally activated with non-thermal red light using a device laser system (called BioBlade® Laser System), which is the medical device used in the combination with cetuximab saratolacan.

    Pre-clinical data shows that following activation, cetuximab saratolacan induces rapid cell membrane disruption of the targeted cancer cells, leading to cell necrosis, and immune-o-genic cell death. Pre-clinical data also shows that cetuximab saratolacan can also induce innate and adaptive anti-cancer immune responses.

    Rakuten Medical is currently conducting a global Phase III multi-center clinical trial with cetuximab saratolacan to evaluate the efficacy and safety in patients with recurrent head and neck squamous cell carcinoma.

    In this program we talk about the platform technology and the regulatory aspects of developing this novel approach. We also talk about clinical trials, trial recruitment and real-world data.

    About The Onco'Zine Brief
    The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

    For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief

    For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

    To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

    Note
    * Previously know as Aspyrian Therapeutics

    References
    [1] Kobayashi H, Choyke PL. Near-Infrared Photoimmunotherapy of Cancer. Acc Chem Res. 2019 Aug 20;52(8):2332-2339. doi: 10.1021/acs.accounts.9b00273. Epub 2019 Jul 23. PMID: 31335117; PMCID: PMC6704485.
    [2] Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 2002;7 Suppl 4:2-8. doi: 10.1634/theoncologist.7-suppl_4-2. PMID: 12202782.

    • 49 min
    C3 – Looking for Ideas Beyond Medicine to Change Cancer Care

    C3 – Looking for Ideas Beyond Medicine to Change Cancer Care

    In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Anthony Yanni, M.D., Senior Vice President, patient-centricity at Astellas. In this role, Yanni is responsible for leading the development and execution of Astellas’ global patient-centricity strategy.

    To understand patient centricity, consider the fact that 10 years ago, patient-centricity wasn’t even a concept – In most cases, drugs were developed if scientists could achieve innovation, without considering if companies should actually develop a medicine based on the real-world unmet medical needs and the perspectives of the patient.

    And while ‘patient-centricity’ has become an industry’s catchphrase, not everyone has the same understanding of its true meaning. The concept of 'patient-centricity' comes from the United Kingdom’s National Health Service -idea of “no decision about me, without me.”

    But 'Patient-centricity' is more than a catchphrase.

    In the most advanced form, it is about the meaningful use of insights from patients - to support the development of health solutions, including the development of novel therapeutics.

    The essence of patient-centricity requires companies to have a 'listening ear' – to listen to the patient, to listen to what they think and understand – and really understand what they mean.

    According to a number of peer-reviewed studies patient-centricity – and with that - increased engagement with patients and providers leads to better care, decreased levels of disease, and a decrease of overall health-related expenses.

    In this process Information is essential. Information may help all participants involved in this process to have a better understanding of a particular disease and the individual, unmet medical needs of the patient.

    If patient-centricity is to succeed, engaging with the patient at a much earlier stage than has traditionally been the case may be essential. For example, patients, patient advocates, and their organizations may help in the drug development phase, including clinical trial design.

    By doing so, pharma – and in its wake the entire life sciences industry - can then leverage the patients’ expertise and detailed knowledge of their own disease and their own medical history to provide more effective patient-centric care.

    In his role as Senior Vice President and Head of Patient Centricity at Astellas, Yanni is responsible for leading the development and execution of the company’s global patient-centricity strategy. In that capacity, he helps guide the company to really understand the patient journey in a real-world setting - along with the continued development of a patient-focused corporate culture.

    In his view, medicine is more than a novel drug: “At the end of the day,” Yanni notes, “we are not here to treat a patient – we’re here to care for a person. Having a conscious awareness of that person in every activity, from every area of the company, every single day, ensures we will create truly meaningful innovations.”

    More than ever before, there is a need for meaningful innovation that can ease the challenges and worries patients and their caregivers have. And this is particularly so amid the current COVID-19 pandemic.

    In their process of listing to the patient, Astellas Oncology, years ago, established the Changing Cancer Care or C3 Prize.

    This prize is more than a listening exercise. It’s an effort to foster innovation in cancer care beyond medicine and change the entire experience for patients, caregivers, and loved ones.

    The C3 Prize is open to anyone with a great idea to change cancer care. Past winners have developed charity initiatives, patient education programs, apps, augmented reality experiences, and other programs aimed at changing the overall experience of cancer care. Any idea that can have an impact, especially if it is...

    • 47 min

Top podcasts em Ciência